|
|
Home>Breast Cancer> Kyowa Hakko Kogyo Obtains Additional Approval for Its Antitumor Agents
Kyowa Hakko Kogyo Obtains Additional Approval for Its Antitumor Agents
Tokyo (JCNN) - Kyowa Hakko Kogyo (TSE: 4151) announced on June 3 that it has received approval for an additional
indication of its antitumor agents Navelbine Injection 40 and Navelbine Injection 10, from the Ministry of Health, Labor and
Welfare, Japan, as of May 31.
Navelbine Injection 40 and Navelbine Injection 10 are now available for the treatment of inoperable or recurrent breast
cancer.
Navelgine Injection (vinorelbine tartrate), which has been marketed in Japan since 1999, is currently distributed in over 70
countries worldwide.
View Kyowa Hakko Kogyo Co. Ltd. company
profile here
Copyright ?2005 JCNN. All rights reserved. A division of Japan Corporate News Network KK.
 
|
|
